de Carvalho Fabíola V, Geronimo Gabriela, de Moura Ludmilla D, Mendonça Talita C, Breitkreitz Márcia Cristina, de Paula Eneida, Rodrigues da Silva Gustavo H
Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP), 13083-862 Campinas, São Paulo, Brazil.
Department of Analytical Chemistry, Institute of Chemistry, University of Campinas (UNICAMP), 13083-970 Campinas, São Paulo, Brazil.
ACS Omega. 2025 May 22;10(21):21568-21580. doi: 10.1021/acsomega.5c00689. eCollection 2025 Jun 3.
Although chemotherapy regimens are well-established in clinical practice, chemoresistance and adverse side effects pose significant obstacles in cancer treatment. Paclitaxel (PTX), a widely used chemotherapeutic agent, faces formulation challenges due to its poor solubility and permeability. Research suggests that the phytochemical Cannabidiol (CBD) holds potential not only in targeting cancer cells but also in alleviating pain and nausea, thereby improving the quality of life for cancer patients. However, CBD's clinical application is also limited by its poor solubility, low bioavailability, and susceptibility to oxidation. Nanostructured lipid carriers (NLCs) represent a promising drug delivery system for hydrophobic compounds like PTX and CBD and allow their coencapsulation. Nonetheless, achieving a stable formulation requires the identification of suitable preparation methods and excipients. The aim of this study was to develop and optimize an NLC formulation for the coencapsulation of PTX and CBD. Using factorial design, an optimized formulation was obtained with homogeneous particle sizes (200 nm), negative ZPs (-16.1 mV), a particle concentration of 10 particles/mL, spherical morphology (TEM images), and a lipid core with low crystallinity (confirmed by XRD). To evaluate the therapeutic potential of the drug combination, cell viability assays were conducted on murine melanoma cells (B16-F10) at different exposure times (24 and 48 h). The NLC-CBD-PTX formulation significantly reduced cell viability in a time- and concentration-dependent manner, demonstrating at least 75% greater activity at 24 h compared to each drug individually, whether free (PTX, CBD) or encapsulated (NLC-PTX, NLC-CBD). This indicates a synergistic effect between CBD and PTX when coencapsulated, particularly at higher concentrations and shorter exposure times. In conclusion, an innovative pharmaceutical formulation coencapsulating PTX and CBD was validated, showing potential to enhance antitumor efficacy, overcome chemoresistance, reduce side effects, and broaden therapeutic applications. The resulting NLCs exhibited favorable physicochemical properties, supporting their suitability for various routes of administration.
尽管化疗方案在临床实践中已得到充分确立,但化疗耐药性和不良副作用在癌症治疗中构成了重大障碍。紫杉醇(PTX)是一种广泛使用的化疗药物,由于其溶解性和渗透性差而面临制剂挑战。研究表明,植物化学物质大麻二酚(CBD)不仅在靶向癌细胞方面具有潜力,而且在减轻疼痛和恶心方面也有潜力,从而提高癌症患者的生活质量。然而,CBD的临床应用也受到其溶解性差、生物利用度低和易氧化的限制。纳米结构脂质载体(NLCs)是一种有前途的药物递送系统,可用于递送PTX和CBD等疏水性化合物,并允许它们共包封。尽管如此,要获得稳定的制剂需要确定合适的制备方法和辅料。本研究的目的是开发和优化一种用于共包封PTX和CBD的NLC制剂。采用析因设计,获得了一种优化制剂,其粒径均匀(200 nm)、Zeta电位为负(-16.1 mV)、颗粒浓度为10个颗粒/mL、呈球形形态(透射电镜图像)且脂质核心结晶度低(X射线衍射证实)。为了评估药物组合的治疗潜力,在不同暴露时间(24小时和48小时)对小鼠黑色素瘤细胞(B16-F10)进行了细胞活力测定。NLC-CBD-PTX制剂以时间和浓度依赖性方式显著降低细胞活力,与单独使用每种药物(无论是游离的(PTX、CBD)还是包封的(NLC-PTX、NLC-CBD))相比,在24小时时显示出至少75%更高的活性。这表明CBD和PTX共包封时具有协同作用,特别是在较高浓度和较短暴露时间下。总之,一种共包封PTX和CBD的创新药物制剂得到了验证,显示出增强抗肿瘤疗效、克服化疗耐药性、减少副作用和拓宽治疗应用的潜力。所得的NLCs表现出良好的物理化学性质,支持它们适用于各种给药途径。
Exp Dermatol. 2024-7
Eur J Pharm Biopharm. 2023-3
J Control Release. 2023-1